A 1 -A 2 9 8 A59 OBJECTIVES: Buprenorphine/naloxone combination (BUP/NAL) has been available in a film formulation since 2010 for the treatment of opioid dependence. A clinical trial showed that patients preferred the film to tablet formulation. Insurance claims data extracted from MarketScan Medicaid database were analyzed to compare patient persistence and health care costs between the two formulations. METHODS: Patients initiating treatment with BUP/NAL after the launch of film (September 2010) were classified in two groups according to formulation of initial prescription: film or tablet. Time to treatment discontinuation and monthly health care costs by treatment phase (before treatment, initiation period, during treatment, discontinuation period, after discontinuation and reinitiation period) were compared between the two groups, adjusting on baseline characteristics (demographics, comorbidities, treatment, and resource utilization before treatment). RESULTS: Analysis included 450 patients initially treated with film and 1127 with tablet, followed over 6.3 and 8.0 months on average respectively. Of those treated with tablet, 17.8% of patients switched to film. The average dose at initiation was 16 mg in both groups. Kaplan-Meier estimates of the probability of persistence 200 days were 59.11% and 51.46% in the film and tablet groups respectively. The hazard ratio for treatment discontinuation with film versus tablet, adjusted on baseline characteristics, was 0.72 (p=0.02). Monthly costs were highest around the time of treatment initiation, switch and discontinuation. Monthly costs during treatment were $418.76 for patients treated with film and $477.66 with tablet (p=0.1561). Monthly costs after treatment discontinuation were 40% lower among patients treated with film (p=0.0354). CONCLUSIONS: Patients treated with BUP/NAL film appear to have a lower probability of early treatment discontinuation. Treatment with the film formulation may generate cost savings since costs around discontinuation are relatively high, and costs after treatment discontinuation were found to be lower among patient previously treated with film.
PMH23 DIRECT AND INDIRECT COSTS AMONG US EMPLOYEES WITH AND WITHOUT BIPOLAR DISORDER OR SCHIZOPHRENIA: ANNUAL COST TRENDS FROM 2001 TO 2011
Brook RA 1 , Rajagopalan K 2 , Kleinman NL 3 , Hassan M 2 , Young JW 4 , Smeeding JE 5 , Pikalov A 6 1 The JeSTARx Group, Newfoundland, NJ, USA, 2 Sunovion Pharmaceuticals, Inc., Marlborough, MA, USA, 3 The HCMS Group, Cheyenne, WY, USA, 4 HCMS Group, Cheyenne, WY, USA, 5 The JeSTARx Group, Dallas, TX, USA, 6 Sunovion Pharmaceuticals, Inc., Fort Lee, NJ, USA OBJECTIVES: Given bipolar disorder (BPD) and schizophrenia impose a significant burden in the workplace, this study evaluated the annual costs among US employees with BPD or schizophrenia. METHODS: Analysis of 2001-2012 HCMS database from subjects with BPD/schizophrenia diagnostic claims and ≥12 months follow-up after their index-date and subjects without BPD/schizophrenia (controls). Index date was defined as: (i) initial claim date for subjects with BPD or schizophrenia and (ii) average of BPD and schizophrenia index date by year for controls. Inflation-adjusted annual costs including medical, Rx, sick leave (SL), short-term disability (STD) and workers' compensation (WC) were compared between cohorts using two-part regression, controlling for confounders. RESULTS: Total annual costs among BPD subjects (n=5299) were higher compared to controls (n=653,707) in 2001 (+$8573) and 2011 (+$9547), respectively. Differences were significant (P<0.005) in all costs categories in 2001 (Medical=$4701, Rx=$2252, SL=$391, STD=$762, and WC=$461) and in 2011(Medical=$6147, Rx=$2552, SL=$208 and STD=$413). Total costs, medical costs and Rx costs were higher among schizophrenia (n=391) subjects than controls in the years 2001 (+$8,812, +$6549 and +$2119), and 2011 (+$7772, +$5191, and +$2630), respectively. In 2001, BPD subjects' costs were $239 lower than schizophrenia despite significantly higher STD (+$649) and WC (+$666) costs. In 2011, however, subjects with BPD incurred greater costs than those with schizophrenia ($1775; P>0.05). From years 2001-2011, BPD subjects' medical costs increased (+$1950) and STD costs decreased (-$473). Consistent decreases in STD costs were observed among the BPD subjects since 2006, and direct medical costs as a percent of total costs increased from 78.9%-86.7% for BPD subjects and from 75.2%-78.8% for controls. CONCLUSIONS: In this employer database, STD costs have become marginally lower since 2006. However, medical costs (e.g., ER/inpatient visits) among these patient populations still remain high, suggesting the need for therapeutic options with a lower medical cost burden. Patients with an admitting primary or secondary diagnosis of schizophrenia during the study period were eligible for inclusion. Patients were classified as having 0, 1, 2, or 3+ metabolic comorbidities based upon diagnoses of diabetes mellitus, hyperglycemia, hypertension, dyslipidemia, coronary heart disease, ischemic heart disease, or cardiovascular disease (CVD) during their index hospitalization. Generalized linear models were used to compare costs across the 4 comorbidity cohorts (0, 1, 2, 3+). Logistic regressions were used to compare the likelihood of readmission and the likelihood of death among the comorbidity cohorts. RESULTS: A total of 57,506 patients met all inclusion criteria; 33.9% with 0 comorbidities, 26.7% with 1 comorbidity, 19.9% with 2 comorbidities, and 19.4% with 3 or more comorbidities. Among patients with comorbidities, 57% had hypertension, 28% had diabetes, 30% had hyperlipidemia, 10% had coronary/ischemic heart disease, 4% had CVD, and 2% had hyperglycemia. As the number of comorbidities increased from 0 to 3+, there were increases in medical costs ($9,619 to $13,111; P<0.0001) , pharmacy costs ($501 to $1,540; P<0.0001), and total costs ($10,120 to $14,651; P<0.0001). Patients with a higher number of comorbidities were more likely to have a readmission for any cause (9% to 13%; P<0.0001) and die during their index hospitalization (0.3% to 2%; P<0.0727), although increases in mortality were not statistically significant. CONCLUSIONS: A high prevalence of metabolic comorbidities was found in this study population of hospitalized schizophrenia patients. An increase in the number of metabolic comorbidities had adverse clinical and economic consequences, including increased costs and readmission rates. The proportion of the total national indirect costs for 'all mental illnesses' (based on DSM IV criteria) that were attributable to Texas patients was estimated and this ratio was applied to the national indirect costs for schizophrenia (ICD9 code of 295) to estimate costs attributable to Texas patients. Categories for indirect costs included: restricted activity-associated costs (based on number of work days missed), reduced employment costs (based on difference in wages for patients with versus without schizophrenia), premature mortality costs (based on percentage of patients who commit suicide times discounted wages lost), and caregivers' costs (based on days of work missed by an unpaid caregiver). These estimates were adjusted to 2008 dollars and summed to obtain the 2005-2008 total 4-year indirect costs for patients with schizophrenia in Texas. All analyses were carried out using the 'survey' procedure of SAS in order to account for the complex sample design of MEPS. RESULTS: For community-dwelling patients with schizophrenia in Texas (weighted n = 153,872 patient years), the mean indirect costs per patient year were about $17,000. The estimated productivity cost per patient-year due to reduced employment, premature mortality, restricted activity and caregivers' cost was $16,572, $215, $67, and $50 respectively. The total indirect costs for patients with schizophrenia in this Texas population between 2005 and 2008 amounted to about $2.6 billion, or about $650 million per year. These estimates did not include costs for homeless, institutionalized, or incarcerated patients. CONCLUSIONS: This study highlights the high financial burden of indirect costs for community-dwelling patients with schizophrenia, most of which were due to reduced employment.
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